

# Companion handbook

to the WHO guidelines for the  
programmatic management of  
drug-resistant tuberculosis



World Health  
Organization



# Companion handbook

**to the WHO guidelines for the  
programmatic management of  
drug-resistant tuberculosis**



**World Health  
Organization**

This book is a companion handbook to existing WHO policy guidance on the management of multidrug-resistant tuberculosis, including the *WHO guidelines for the programmatic management of drug-resistant tuberculosis*, *WHO interim policy guidance on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis*, and the *WHO interim policy guidance on the use of delamanid in the treatment of multidrug-resistant tuberculosis* which were developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the WHO Handbook for Guideline Development (version March 2010; available at [http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf)).

#### WHO Library Cataloguing-in-Publication Data

Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.

1. Antitubercular agents – administration and dosage. 2. Tuberculosis, Multidrug-Resistant – drug therapy. 3. Treatment outcome. 4. Guideline. I. World Health Organization.

ISBN 978 92 4 154880 9

(NLM classification: WF 360)

#### © World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

WHO/HTM/TB/2014.11

Editing and design by Inis Communication – [www.iniscommunication.com](http://www.iniscommunication.com)

# Contents

Abbreviations and acronyms . . . . .	vi
Acknowledgements. . . . .	ix
Foreword. . . . .	1
Executive summary . . . . .	2
Methods and process for developing the Handbook . . . . .	4

## **PART 1 – PREVENTION AND DRUG-RESISTANT TB DIAGNOSIS, TREATMENT AND CARE**

1. Prevention of drug-resistant tuberculosis . . . . .	7
2. Monitoring the detection, enrolment and treatment outcomes of drug-resistant TB patients . . . . .	15
3. Laboratory . . . . .	39
4. Case finding for drug-resistant TB . . . . .	61
5. Treatment strategies for MDR-TB and XDR-TB . . . . .	75
6. Mono- and poly-resistant strains (drug-resistant TB other than MDR-TB) . . . . .	100
7. Treatment of drug-resistant TB in special conditions and situations. . . . .	106
8. Drug-resistant TB and HIV . . . . .	118
9. Initiating treatment . . . . .	134
10. Monitoring treatment response . . . . .	139
11. Management of adverse effects and pharmacovigilance. . . . .	145
12. Patient-centred care, social support and adherence to treatment . . . . .	181
13. Palliative and end-of-life care . . . . .	193
14. Drug resistance and infection control . . . . .	198
15. Management of contacts of MDR-TB patients . . . . .	203

## **PART 2 – PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TB**

16. The global response to drug-resistant TB . . . . .	209
17. Managerial aspects of the programmatic management of drug-resistant TB . . . . .	216
18. Models for delivering MDR-TB treatment and care . . . . .	225

19. Community engagement to support universal access to diagnosis, care and treatment of drug-resistant TB . . . . .	233
20. Managing medicines for drug-resistant TB . . . . .	239
21. Ethics in programmatic management of MDR-TB . . . . .	249
22. Use of drugs under development and preapproval by national drug regulatory authorities . . . . .	255

### **PART 3 – ANTI-TB DRUG INFORMATION SHEETS . . . . . 261**

Amikacin (Am) . . . . .	263
Amoxicillin/Clavulanate (Amx/Clv) . . . . .	265
Bedaquiline2 (Bdq) . . . . .	266
Capreomycin (Cm) . . . . .	269
Clofazimine (Cfz) . . . . .	273
Cycloserine (Cs) [and Terizidone (Trd)] . . . . .	274
Delamanid (Dlm) . . . . .	275
Ethambutol (Emb) . . . . .	278
Ethionamide (Eto)/Protionamide (Pto) . . . . .	280
Gatifloxacin (Gfx) . . . . .	282
Imipenem (Imp)/Cilastatin (Cln) . . . . .	284
Isoniazid (Inh) . . . . .	286
Kanamycin (Km) . . . . .	288
Levofloxacin (Lfx) . . . . .	290
Linezolid (Lzd) . . . . .	292
Meropenem (Mpm) . . . . .	294
Moxifloxacin (Mfx) . . . . .	296
Para-aminosalicylic acid (PAS) . . . . .	298
Pyrazinamide (Pza) . . . . .	300
Rifabutin (Rfb) . . . . .	302
Rifampin (Rif) . . . . .	304
Rifapentine (Rpt) . . . . .	306
Streptomycin (S) . . . . .	308

### **PART 4 – FORMS FOR DRUG-RESISTANT TB PROGRAMMES . . . . . 309**

Form 01: Second-line TB treatment card . . . . .	310
Form 02: Second-line TB treatment register . . . . .	314
Form 03: Request for examination of biological specimen for TB . . . . .	318
Form 04: Laboratory register for culture, Xpert MTB/RIF and drug susceptibility testing (DST) . . . . .	319

## CONTENTS

Form 05: Six-monthly report on detection of TB cases with rifampicin resistance (RR-TB) and multidrug resistance (MDR-TB) . . . . .	322
Form 06: Six-monthly report on enrolment of TB cases with rifampicin resistance (RR-TB) and multidrug resistance (MDR-TB) on second-line TB treatment . . . . .	323
Form 07: Quarterly report on interim results of TB cases with rifampicin resistance (RR-TB) and multidrug resistance (MDR-TB) on second-line TB treatment . . . . .	324
Form 08: Annual report of final outcomes of TB cases with rifampicin resistance (RR-TB), multidrug resistance (MDR-TB) and extensive drug resistance (XDR-TB) on second-line TB treatment . . . . .	325

## PART 5 – ANNEXES

Annex 1. Suggestions for further reading and available training materials and tools . . . . .	326
Annex 2. Weight-based dosing for adults . . . . .	332
Annex 3. Weight-based dosing for children . . . . .	334
Annex 4.1. ‘How-to’ guide on the use of bedaquiline for MDR-TB treatment . . . . .	341
Annex 4.2. ‘How-to’ guide on the use of delamanid for MDR-TB treatment . . . . .	369
Annex 4.3. Key points on the summary of evidence in the use of bedaquiline and delamanid in MDR-TB treatment . . . . .	398
Annex 4.4. Summary information on clinical and programmatic aspects of the new anti-TB drugs bedaquiline and delamanid . . . . .	400
Annex 4.5. Deciding between bedaquiline and delamanid for the treatment of MDR-TB . . . . .	406
Annex 5. Indicators for monitoring drug-resistant TB programmes . . . . .	407
Annex 6. Schedule of clinical and laboratory follow up . . . . .	414
Annex 7. Management of electrolyte disturbances . . . . .	416
Annex 8. Management strategy for hearing loss . . . . .	419
Annex 9. “How-to” guide for forecasting drugs needs and tools for quantification and forecasting . . . . .	422
Annex 10. Reinforcing the parameters of observational studies for MDR-TB patients on treatment . . . . .	426
Annex 11. Sample forms for Core Package of aDSM . . . . .	441
Annex 12. Adverse events of clinical significance or special interest for aDSM . . . . .	444
Annex 13.1. Sample schedule of routine tests to monitor patients on regimens containing bedaquiline or delamanid (in addition to standard PMDT assessments) . . . . .	445
Annex 13.2. Sample schedule of examinations during intensive, continuation, and follow-up phases for a shorter MDR-TB regimen . . . . .	446

## Abbreviations and acronyms

<b>aDSM</b>	active drug-safety monitoring and management
<b>AFB</b>	acid-fast bacilli
<b>AIDS</b>	acquired immunodeficiency syndrome
<b>ALT</b>	alanine aminotransferase
<b>API</b>	active pharmaceutical ingredients
<b>ART</b>	antiretroviral therapy
<b>AST</b>	aspartate aminotransferase
<b>BCG</b>	Bacillus Calmette–Guérin
<b>BMI</b>	body mass index
<b>BMU</b>	Basic Management Unit
<b>CBO</b>	community-based organization
<b>CDC</b>	United States Centers for Disease Control and Prevention
<b>CHW</b>	community health worker
<b>CMV</b>	cytomegalovirus
<b>CNS</b>	central nervous system
<b>CEM</b>	cohort event monitoring
<b>CPC</b>	cetylpyridinium chloride
<b>CPT</b>	cotrimoxazole preventive therapy
<b>CRI</b>	colourimetric redox indicator
<b>CSO</b>	civil society organization
<b>CU</b>	compassionate use
<b>CYP3A4</b>	cytochrome P450 3A4
<b>DOT</b>	directly-observed therapy
<b>DOTS</b>	core approach underpinning the Stop TB strategy for TB control
<b>DRS</b>	drug resistance surveillance
<b>DST</b>	drug susceptibility testing
<b>EA</b>	expanded access
<b>EQA</b>	external quality assessment
<b>ERP</b>	Expert Review Panel
<b>FBO</b>	faith-based organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27776](https://www.yunbaogao.cn/report/index/report?reportId=5_27776)

